Coronavirus What you need to know Coronavirus in Poland Coronavirus in Europe Coronavirus in the world Guide Map Frequently asked questions #Let’s talk about

More than 136 million people in more than 200 countries have been infected with COVID-19 since the beginning of the pandemic. Reinfections following natural infections with the same or a new variant of SARS-CoV-2 have been reported sporadically. Questions about the duration of immunity after natural infection and whether asymptomatic re-infected individuals might be able to transmit the virus remain unanswered.

  1. Current data show that coronavirus recurrences are rare, but do occur
  2. Scientists estimate that people vaccinated against COVID-19 in the event of reinfection have a lower “load” of the virus, which means that they do not spread the disease as much
  3. For more up-to-date information on the coronavirus, please visit the TvoiLokony home page

Coronavirus Resistance – Still many unknowns

COVID-19 vaccines have been evaluated for their effectiveness in managing symptomatic infection and in reducing and / or preventing mild, moderate or severe disease, including mortality. However, vaccine studies were not designed to measure a reduction in the risk of transmission of the virus from people who were vaccinated to susceptible people with whom they came into contact.

ECDC carried out a review of the scientific literature on the duration and characteristics of immunity following natural infection with SARS-CoV-2 from any variant or vaccination with any currently available vaccine approved in the EU.

Coronavirus: what is the risk of infection from recoveries?

A review of the evidence regarding natural immunity and the possibility of transmission from previously infected individuals showed that:

  1. Reinfection is a rare event. Research results confirm that the protective effect of an earlier SARS-CoV-2 infection ranges from 81%. up to 100 percent from day 14 after the initial infection, for a follow-up period of five to seven months. Protection against reinfection is lower in people aged 65 and over.
  2. A previous SARS-CoV-2 infection does not provide immunity to reinfection in all people, and some re-infected may still transmit SARS-CoV-2 to susceptible contacts.
  3. These studies were conducted prior to the emergence of the worrying new SARS-CoV-2 variants, and therefore there is limited preliminary evidence that the immunity induced against previously circulating SARS-CoV-2 variants may not be of the same strength or duration as previously identified new variants (in particular variants B.1.351 and P.1.)
  4. As the number of individuals acquiring natural immunity increases, the total number of infections is expected to decrease significantly, leading to an overall reduction in transmission, unless genetic alterations in circulating variants result in a significant immune flight.

If you’ve been infected with the SARS-CoV-2 virus, check your body’s condition by doing blood tests for recoveries from COVID-19. You can buy them at Medonet Market.

Coronavirus: What is the Risk of Infection from the Vaccinated?

A review of the evidence regarding immunity and the possibility of virus transmission from previously vaccinated people showed that:

  1. Evidence for the effect of vaccination on the risk of transmission of disease is available from only one study which suggests that vaccinating a household member reduces the risk of infection in other household members by at least 30%.
  2. There is evidence that vaccination significantly reduces viral load and symptomatic / asymptomatic infections in vaccinated individuals, which may translate into reduced transmission, although vaccine efficacy varies with the product administered and the target group. In view of this fact, the total number of infections is expected to decrease significantly as vaccination coverage increases. This will lead to an overall reduction in transmission.
  3. Studies in vaccinated people are not yet long enough to draw conclusions about the length of protection against infection in the long term. Antibody titers in vaccinated individuals peak at 3-4 weeks after vaccination.
  4. Many vaccine efficacy studies were conducted before the emergence of new variants of the SARS-CoV-2 virus. In studies that look at these variants, there is limited preliminary evidence of reduced vaccine efficacy, in particular for variant B.1.351 and possibly P.1 as well.

Author: Magda Mazurek / Medexpress

This may interest you:

  1. They got vaccinated and fell ill. How many such cases in Poland?
  2. How does the virus attack? «It can be compared to the Battle of Grunwald»
  3. These are the most common effects of COVID-19. They last for months

The content of the medTvoiLokony website is intended to improve, not replace, the contact between the Website User and their doctor. The website is intended for informational and educational purposes only. Before following the specialist knowledge, in particular medical advice, contained on our Website, you must consult a doctor. The Administrator does not bear any consequences resulting from the use of information contained on the Website. Do you need a medical consultation or an e-prescription? Go to halodoctor.pl, where you will get online help – quickly, safely and without leaving your home.Now you can use e-consultation also free of charge under the National Health Fund.

Leave a Reply